CIPA.FYI
Research & registriesInternationalEU02

ENISNIP – European Network on Inherited Sensory Neuropathies and Insensitivity to Pain

A research lead concerning specialist collaboration and patient participation.

Scope & limitations

A cross-condition network. Its relationship to CIPA rests on NTRK1 / HSAN level statements rather than CIPA-specific work. The Aachen University Hospital institutional page is used as the source entry.

About these terms

HSAN IV
Where a resource says HSAN IV, it usually means CIPA. MedlinePlus Genetics states that CIPA “is also known as hereditary sensory and autonomic neuropathy type IV”, lists HSAN type IV and HSAN4 as alternative names, and identifies NTRK1 as the gene involved.Based on: MedlinePlus Genetics, U.S. National Library of Medicine
CIP
Some resources use CIP (congenital insensitivity to pain) without the “anhidrosis” qualifier. Its scope is broader than CIPA, and this site does not treat the two as equivalent; where a resource is filed under CIP, its relationship to CIPA is stated in that record’s scope note.Based on: This site’s editorial handling (not a medical claim)

Record details

Source organization
ENISNIP / University Hospital Aachen and collaborators
Regions
International
Research record date
2026-09-21This is not the medical revision date.
Publication status
Publication review complete

Title, version & context

Index title
ENISNIP – European Network on Inherited Sensory Neuropathies and Insensitivity to Pain
Version & date
An EJP RD project funded in 2019; the institutional page was accessible during the recorded review.
Source title

ENISNIP – European Network on Inherited Sensory Neuropathies and Insensitivity to Pain

Relationship to CIPA
Relevant through explicit NTRK1 and broader CIP / HSAN coverage; not exclusively focused on CIPA.

Reading notes

Main audience
Clinicians, researchers, and patients or families interested in the project.
Resource purpose
Learn about collaboration, FAQs and registry enquiries.

The form is an initial enquiry. The team must explain enrolment and data-use conditions; it does not promise treatment or funding.

Related resources

Resources →